Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Throughout my experience with multiple myeloma, I was humbled by the unexpected support and kindness shown to me.

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

People are living longer, living better with multiple myeloma. But I think for the vast majority of people who are diagnosed, we still don't have a curative treatment for multiple myeloma, so that, to ...

So, we now have multiple new classes of drugs, multiple agents that are FDA-approved for the treatment of multiple myeloma, more than 15, 16 different drugs that have become available in that period.

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Looking at the genetic makeup of multiple myeloma cells can help in deciding how aggressive treatment should be and what therapy to take. A fluorescence in situ hybridization test (FISH) is one of the ...

The following is a summary of “Time-dependent recovery of renal impairment in patients with newly diagnosed multiple myeloma, ...

Multiple myeloma is considered the second most common blood cancer, with close to 160,000 new cases diagnosed globally per year. Regardless of the many new treatment modalities being developed for ...

According to Binod Dhakal of the Medical College of Wisconsin, one of the study investigators, the approval gives patients the opportunity for a treatment-free period for their multiple myeloma as ...

New innovative local treatment for osteolytic bone disease in multiple myeloma. ScienceDaily . Retrieved February 7, 2025 from www.sciencedaily.com / releases / 2025 / 01 / 250114125014.htm ...